Literature DB >> 9396465

Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway.

Z Laszik1, A Mitro, F B Taylor, G Ferrell, C T Esmon.   

Abstract

BACKGROUND: The protein C anticoagulant pathway is critical to the control of hemostasis. Thrombomodulin and a newly identified receptor for protein C/activated protein C, EPCR, are both present on endothelium. EPCR augments activation of protein C by the thrombin-thrombomodulin complex. METHODS AND
RESULTS: To gain a better understanding of the relationship between thrombomodulin and EPCR, we compared the cellular specificity and tissue distributions of these two receptors by using immunohistochemistry. EPCR expression was detected almost exclusively on endothelium in human and baboon tissues. In most organs, EPCR was expressed relatively intensely on the endothelium of all arteries and veins, most arterioles, and some postcapillary venules. EPCR staining was usually negative on capillary endothelial cells. In contrast, thrombomodulin was detected at high concentrations in both large vessels and capillary endothelium. Both thrombomodulin and EPCR were expressed poorly on brain capillaries. The liver sinusoids were the only capillaries in which EPCR was expressed at moderate levels and thrombomodulin was low. EPCR and thrombomodulin were both expressed on the endothelium of vasa recta in the renal medulla, the lymph node subcapsular and medullary sinuses, and some capillaries within the adrenal gland. Even in these organs the majority of capillaries were EPCR negative or stained weakly.
CONCLUSIONS: These studies suggest that EPCR may be important in enhancing protein C activation on large vessels. The presence of high levels of EPCR on arterial vessels may help explain why partial protein C deficiency is a weak risk factor for arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396465     DOI: 10.1161/01.cir.96.10.3633

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  82 in total

1.  Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.

Authors:  M M Boomsma; D J Stearns-Kurosawa; C A Stegeman; E Raschi; P L Meroni; S Kurosawa; J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 2.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors:  Shannon M Bates; Jeffrey I Weitz
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

4.  Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.

Authors:  András Gruber; Ulla M Marzec; Leslie Bush; Enrico Di Cera; José A Fernández; Michelle A Berny; Erik I Tucker; Owen J T McCarty; John H Griffin; Stephen R Hanson
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 5.  Plasmodium falciparum picks (on) EPCR.

Authors:  William C Aird; Laurent O Mosnier; Rick M Fairhurst
Journal:  Blood       Date:  2013-11-18       Impact factor: 22.113

6.  Expression and functional characterisation of natural R147W and K150del variants of protein C in the Chinese population.

Authors:  Qiulan Ding; Likui Yang; Seyed Mahdi Hassanian; A R Rezaie
Journal:  Thromb Haemost       Date:  2013-02-07       Impact factor: 5.249

7.  Phosphatidylethanolamine at the luminal endothelial surface--implications for hemostasis and thrombotic autoimmunity.

Authors:  Clive W Wells; Paula E North; Suresh Kumar; Christine B Duris; John A McIntyre
Journal:  Clin Appl Thromb Hemost       Date:  2009-11-10       Impact factor: 2.389

8.  Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion.

Authors:  Jingying Wang; Ji Li
Journal:  Am J Transl Res       Date:  2009-07-15       Impact factor: 4.060

9.  JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

Authors:  S Leah Etheridge; Michelle E Roh; Megan E Cosgrove; Veena Sangkhae; Norma E Fox; Junmei Chen; José A López; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

10.  Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice.

Authors:  S Crikis; X M Zhang; S Dezfouli; K M Dwyer; L M Murray-Segal; E Salvaris; C Selan; S C Robson; H H Nandurkar; P J Cowan; A J F d'Apice
Journal:  Am J Transplant       Date:  2010-01-06       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.